Table 3.

Posttransplant outcomes

MMUD (N = 72)MUD (N = 193)
Alive 37 (51) 87 (45) 
 Median follow-up (range), y 3.5 (1.0-10.1) 4.3 (0.8-12.5) 
 Alive without relapse 30 (42) 58 (30) 
 Off immunosuppression 22 (31) 65 (34) 
 Alive without GVHD or relapse 15 (21) 32 (17) 
 Alive with relapse or disease progression 7 (10) 29 (15) 
  Median time to progression (range), y 0.8 (0.3-2.1) 1.3 (0.1-12.0) 
Deceased 35 (49) 106 (55) 
 Death from relapse or disease progression 22 (31) 75 (39) 
 Death from other cause 13 (18) 31 (16) 
  Acute GVHD 4 (6) 4 (2) 
  Chronic GVHD 4 (6) 8 (4) 
  Infection 2 (3) 8 (4) 
  Secondary malignancy* 2 (3) 3 (2) 
  Other causes of death 1 (1) 8 (4) 
MMUD (N = 72)MUD (N = 193)
Alive 37 (51) 87 (45) 
 Median follow-up (range), y 3.5 (1.0-10.1) 4.3 (0.8-12.5) 
 Alive without relapse 30 (42) 58 (30) 
 Off immunosuppression 22 (31) 65 (34) 
 Alive without GVHD or relapse 15 (21) 32 (17) 
 Alive with relapse or disease progression 7 (10) 29 (15) 
  Median time to progression (range), y 0.8 (0.3-2.1) 1.3 (0.1-12.0) 
Deceased 35 (49) 106 (55) 
 Death from relapse or disease progression 22 (31) 75 (39) 
 Death from other cause 13 (18) 31 (16) 
  Acute GVHD 4 (6) 4 (2) 
  Chronic GVHD 4 (6) 8 (4) 
  Infection 2 (3) 8 (4) 
  Secondary malignancy* 2 (3) 3 (2) 
  Other causes of death 1 (1) 8 (4) 

Data are presented as n (%) unless otherwise indicated.

*

Secondary malignancies include donor-derived myelodysplastic syndrome, diffuse large B-cell lymphoma, gastric adenocarcinoma, rectal adenocarcinoma, and thoracic sarcoma.

Other causes of death include pulmonary embolism, cerebrovascular accident, cardiac arrest, thrombotic thrombocytopenic purpura, and suicide.